The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy
|
|---|---|
| Published in |
Frontiers in Pharmacology, June 2018
|
| DOI | 10.3389/fphar.2018.00582 |
| Pubmed ID | |
| Authors |
Liang Ge, Xinru You, Jun Huang, Yuejian Chen, Li Chen, Ying Zhu, Yuan Zhang, Xiqiang Liu, Jun Wu, Qian Hai |
| Abstract |
For enhanced anti-cancer performance, human serum albumin fragments (HSAFs) nanoparticles (NPs) were developed as paclitaxel (PTX) carrier in this paper. Human albumins were broken into fragments via degradation and crosslinked by genipin to form HSAF NPs for better biocompatibility, improved PTX drug loading and sustained drug release. Compared with crosslinked human serum albumin NPs, the HSAF-NPs showed relative smaller particle size, higher drug loading, and improved sustained release. Cellular and animal results both indicated that the PTX encapsulated HSAF-NPs have shown good anti-cancer performance. And the anticancer results confirmed that NPs with fast cellular internalization showed better tumor inhibition. These findings will not only provide a safe and robust drug delivery NP platform for cancer therapy, but also offer fundamental information for the optimal design of albumin based NPs. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 27% |
| Student > Master | 3 | 12% |
| Student > Bachelor | 2 | 8% |
| Researcher | 2 | 8% |
| Professor | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 8 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 5 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Biochemistry, Genetics and Molecular Biology | 3 | 12% |
| Chemical Engineering | 2 | 8% |
| Engineering | 2 | 8% |
| Other | 4 | 15% |
| Unknown | 7 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2018.
All research outputs
#20,523,725
of 23,092,602 outputs
Outputs from Frontiers in Pharmacology
#10,319
of 16,442 outputs
Outputs of similar age
#287,929
of 328,357 outputs
Outputs of similar age from Frontiers in Pharmacology
#225
of 389 outputs
Altmetric has tracked 23,092,602 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,357 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 389 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.